Investor News

Investor News

Rights issue enables market expansion

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.

Read more

Digital Holographic Microscopy for biomarker detection in cancer

“In the near future”, Zahra El-Schich says, “you could have a HoloMonitor in every clinic. You could also customize cancer treatment for every patient by just using a simple tumor test.” Find out how.

Read more

Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)

Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.

Read more

New CEO commentary: “Understanding Skin Cancer”

PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.

Read more

Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.

Read more

Fighting cancer at an early stage

Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.

Read more

PHI´s new software available for customer delivery

In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.

Read more

Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)

Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.

Read more

PHI and BioSpherix sign co-marketing agreement

Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.

Read more

Biostock interview with CEO Peter Egelberg

Interview with CEO Peter Egelberg (Swedish) on biostock.se where he talks about PHI’s progress, where PHI is right now and where PHI wants to be in the near future. “Our goal is to be top of mind when researchers and scientists worldwide are looking for a new cell analytic tool”. You find the interview here.

Read more